ALLR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALLR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Allarity Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2024 was $0.30 Mil. Allarity Therapeutics's average total debt for the quarter that ended in Dec. 2024 was $1.34 Mil. Therefore, Allarity Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 was 22.33%.
The historical data trend for Allarity Therapeutics's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allarity Therapeutics Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | 17.63 | 34.11 | 9.25 | 19.78 | 49.28 |
Allarity Therapeutics Quarterly Data | |||||||||||||||||||
Dec19 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Effective Interest Rate on Debt % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
74.58 | 20.45 | 84.88 | 15.03 | 22.33 |
For the Biotechnology subindustry, Allarity Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Allarity Therapeutics's Effective Interest Rate on Debt % falls into.
Allarity Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (A: Dec. 2023 ) | + | Total Debt (A: Dec. 2024 )) | / count ) |
= | -1 * -0.653 | / | ( (1.3 | + | 1.35) | / 2 ) |
= | -1 * -0.653 | / | 1.325 | |||
= | 49.28 % |
where
Total Debt (A: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0 | + | 1.3 |
= | 1.3 |
Total Debt (A: Dec. 2024 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0 | + | 1.35 |
= | 1.35 |
Allarity Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (Q: Sep. 2024 ) | + | Total Debt (Q: Dec. 2024 )) | / count ) |
= | -1 * -0.3 | / | ( (1.337 | + | 1.35) | / 2 ) |
= | -1 * -0.3 | / | 1.3435 | |||
= | 22.33 % |
where
Total Debt (Q: Sep. 2024 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0 | + | 1.337 |
= | 1.337 |
Total Debt (Q: Dec. 2024 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0 | + | 1.35 |
= | 1.35 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.
Allarity Therapeutics (NAS:ALLR) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Thank you for viewing the detailed overview of Allarity Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.
Laura Benjamin | director | 168 GOODRICH ST., LUNENBURG MA 01462 |
Joseph Walter Vazzano | director | 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Gerald W. Mclaughlin | director | 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428 |
David Roth | director | C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Joan Yvonne Brown | officer: Chief Financial Officer | C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434 |
Steve Carchedi | director, officer: Chief Executive Officer | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Steen Knudsen | officer: Chief Scientific Officer | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Jens Erik Knudsen | officer: Chief Financial Officer | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Soren Gade Jensen | director | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Duncan Moore | director | C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432 |
Thomas Jensen | officer: SVP, Information Technology | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
James G. Cullem | officer: SVP, Chief Business Officer | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Marie Foegh | officer: Chief Medical Officer | 210 BROADWAY, STE 201, CAMBRIDGE MA 02139 |
Sass & Larsen Aps | 10 percent owner | VESTERGARDSVEJ 6, GREVE G7 DK-2670 |
Leon Sass | 10 percent owner | JERNBAEK ALLE 5, HELSINGE G7 DK-3200 |
From GuruFocus
By Marketwired • 11-06-2024
By Marketwired • 11-06-2024
By PRNewswire • 03-19-2025
By PRNewswire • 11-12-2024
By PRNewswire • 11-08-2024
By Marketwired • 11-08-2024
By Marketwired • 11-14-2024
By Marketwired • 03-06-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.